Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com -- Fujifilm Holdings Corporation (TSE:4901) has announced its 4Q results, reporting ¥868.3bn ($7.8bn) in sales, a rise of 7.8% year on year, and 4.1% excluding the effects of foreign exchange. The company’s operating profit (OP) was ¥106.9bn ($964m), a significant increase of ¥35.1bn ($316m) from the previous year, and ¥34.6bn ($312m) excluding foreign exchange effects.
The growth in sales and profit was attributed to increased sales and profits from asset sales. The reported OP surpassed the company’s guidance by ¥15.7bn ($141m), driven by profits from asset sales and other items.
The company’s 4Q results exceeded both company and market expectations. The company had set targets of ¥822.4bn ($7.4bn) in sales and ¥91.7bn ($827m) in OP, while market estimates were ¥821.3bn ($7.4bn) in sales and ¥93.2bn ($840m) in OP.
The company’s imaging and business innovation segments outperformed expectations, exceeding projections by ¥9.2bn ($83m) and ¥6.6bn ($60m) respectively, while the electronics segment was in line with the upward-revised value from 3Q. The healthcare segment, however, fell short by ¥2.4bn ($22m).
The healthcare business reported ¥310.0bn ($2.8bn) in 4Q sales, a 9.0% YoY increase, marking the first rise in three quarters. The segment also reported ¥1,022.6bn ($9.2bn) in FY3/25 sales, a 4.9% increase, surpassing ¥1trn for the first time.
Medical (TASE:BLWV) systems, part of the healthcare business, reported ¥206.1bn ($1.9bn) in 4Q sales, an 8.4% increase, with sales to China recovering. The business also posted ¥693.2bn ($6.3bn) in full-year sales, a 5.1% increase, beating guidance by ¥13.2bn ($119m).
The Bio CDMO business reported ¥73.0bn ($658m) in 4Q sales, an 18.1% increase, and ¥219.5bn ($1.98bn) in full-year sales, a 7.9% increase, exceeding the plan target by ¥19.5bn ($176m).
The Life Sciences (LS) solutions segment, however, reported a decrease in sales, with ¥30.9bn ($279m) in 4Q sales, a 4.5% decrease, and ¥109.8bn ($991m) in FY3/25 sales, a 2.0% decrease, missing guidance by ¥10.2bn ($92m).
The healthcare segment’s operating profit was ¥44.8bn ($404m) in 4Q, an increase of ¥7.7bn ($69m) YoY, but fell short of the target by ¥2.4bn ($22m). One-time costs were ¥6.6bn ($60m) higher than planned, and real profit excluding this portion fell short by ¥9.2bn ($83m).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.